D'Alo', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 4.681
EU - Europa 4.202
AS - Asia 1.330
OC - Oceania 128
AF - Africa 55
SA - Sud America 46
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.444
Nazione #
US - Stati Uniti d'America 4.585
DE - Germania 1.638
CN - Cina 859
SE - Svezia 627
IT - Italia 499
UA - Ucraina 299
PL - Polonia 229
GB - Regno Unito 217
FR - Francia 191
SG - Singapore 157
IE - Irlanda 149
IN - India 125
AU - Australia 115
CA - Canada 84
FI - Finlandia 84
RU - Federazione Russa 66
TR - Turchia 46
CI - Costa d'Avorio 25
IR - Iran 24
NL - Olanda 24
RO - Romania 22
BE - Belgio 18
BR - Brasile 18
CH - Svizzera 18
JP - Giappone 18
ES - Italia 16
VN - Vietnam 14
NZ - Nuova Zelanda 13
AT - Austria 12
CZ - Repubblica Ceca 12
HU - Ungheria 11
ID - Indonesia 11
AR - Argentina 10
IL - Israele 10
MX - Messico 10
PT - Portogallo 10
KR - Corea 9
NO - Norvegia 9
GR - Grecia 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
BG - Bulgaria 7
CL - Cile 7
DZ - Algeria 7
HK - Hong Kong 7
ZA - Sudafrica 7
EG - Egitto 6
HR - Croazia 6
SK - Slovacchia (Repubblica Slovacca) 6
CO - Colombia 5
LB - Libano 5
TH - Thailandia 5
DK - Danimarca 4
MK - Macedonia 4
NP - Nepal 4
SA - Arabia Saudita 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GH - Ghana 3
LV - Lettonia 3
MA - Marocco 3
RS - Serbia 3
TN - Tunisia 3
DO - Repubblica Dominicana 2
EC - Ecuador 2
EE - Estonia 2
GE - Georgia 2
IS - Islanda 2
JO - Giordania 2
PK - Pakistan 2
QA - Qatar 2
UY - Uruguay 2
A1 - Anonimo 1
BD - Bangladesh 1
BO - Bolivia 1
EU - Europa 1
IQ - Iraq 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MM - Myanmar 1
PH - Filippine 1
PY - Paraguay 1
SC - Seychelles 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 10.444
Città #
Chandler 643
Ashburn 305
Jacksonville 232
Warsaw 208
Beijing 187
Houston 160
Nanjing 157
Dearborn 147
Dublin 143
San Mateo 143
Ann Arbor 140
Woodbridge 137
Fairfield 129
Wilmington 111
Nürnberg 108
Milan 107
Singapore 107
Hangzhou 103
New York 96
Redwood City 94
Seattle 88
Rome 73
Bremen 68
Chicago 63
Nanchang 58
Cattolica 53
Los Angeles 53
Moscow 53
Lawrence 52
Boston 47
Munich 46
Kunming 36
Izmir 35
Marseille 35
Cambridge 31
Lancaster 30
Shenyang 27
Abidjan 25
Guangzhou 25
Sydney 25
Shanghai 24
Helsinki 23
Adelaide 22
Phoenix 21
Princeton 21
Hebei 20
Hefei 20
Leawood 20
Auburn Hills 19
Brisbane 19
Fremont 19
Changsha 18
Jiaxing 18
Melbourne 18
Brooklyn 17
Mountain View 17
University Park 16
London 15
Philadelphia 15
Portland 15
Redmond 15
San Diego 15
Tianjin 15
Zhengzhou 15
Boardman 14
Norwalk 14
Brussels 13
Jinan 13
San Francisco 13
Augusta 12
Berlin 12
Pune 11
Buffalo 10
Costa Mesa 10
Atlanta 9
Hanoi 9
Hermosillo 9
Lanzhou 9
Toronto 9
Chengdu 8
Detroit 8
Falls Church 8
Kish 8
Monmouth Junction 8
Pittsburgh 8
San Antonio 8
San Jose 8
Traverse City 8
Tübingen 8
Washington 8
Amsterdam 7
Auckland 7
Bologna 7
Hyderabad 7
Knoxville 7
Lebanon 7
Naples 7
Padova 7
San Martino Buon Albergo 7
Andover 6
Totale 5.141
Nome #
VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS 2.142
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 349
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy 281
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 263
DNMT1-interacting RNAs block gene-specific DNA methylation 250
THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA 227
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 205
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 201
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 180
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 168
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 166
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 165
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 163
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 153
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 148
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 144
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 135
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 132
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 131
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 130
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 129
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 126
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 124
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 123
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 121
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 118
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 117
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 117
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 113
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 111
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 110
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 105
Epigenetic changes in therapy-related MDS/AML 103
A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia 102
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 100
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 98
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 97
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 97
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 95
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 95
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 95
Outcome of therapy-related myeloid neoplasms treated with azacitidine 93
PU.1 and CEBPA expression in acute myeloid leukemia. 93
Intravascular large-B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. 91
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 89
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 89
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 89
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 87
Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma 87
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 86
Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3 83
Mantle cell lymphoma relapsing at the lymphedematous arm 83
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 83
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 82
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment 81
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 80
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 76
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 76
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 76
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma 75
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 74
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 73
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 70
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 68
The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL) 66
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy 62
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 61
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 56
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing 54
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma 51
Secondary Orbital and Intraocular Lymphoma Treated With Immunochemotherapy 50
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab 48
Absence of structural mutations of the BAK gene in B cell lymphomas 44
Severe cmv infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in a mantle cell lymphoma old patient 42
Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden 25
Enhancing lymphoma diagnosis on core needle biopsies: Integrating immunohistochemistry with flow cytometry 24
CAR-T Cell Therapy for Follicular Lymphomas 22
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas 9
Endoscopic Ultrasound-Guided Fine Needle Biopsy in the Diagnostic Work-Up of Deep-Seated Lymphadenopathies and Spleen Lesions: A Monocentric Experience 9
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 9
Aggiornamenti di Diagnostica Molecolare in Ematologia 8
Case of metastatic melanoma in bone marrow smear 8
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 7
May we routinely spare hippocampal region in primary central nervous system lymphoma during whole brain radiotherapy? 6
Totale 10.574
Categoria #
all - tutte 29.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.909


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.221 0 0 124 120 144 172 131 66 128 107 134 95
2020/20211.176 42 99 46 102 110 116 125 34 110 89 259 44
2021/2022877 106 84 15 28 66 37 26 134 53 73 123 132
2022/20231.871 254 262 130 322 113 215 95 141 180 39 74 46
2023/20241.670 52 260 71 88 113 197 79 108 81 150 230 241
2024/2025630 296 205 129 0 0 0 0 0 0 0 0 0
Totale 10.574